Research programme: colorectal cancer therapeutics - Genomics Collaborative/ActivX Bioscience
Latest Information Update: 10 Nov 2006
At a glance
- Originator ActivX Biosciences; Genomics Collaborative
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 10 Nov 2006 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route)
- 02 Apr 2003 No development reported - Preclinical for Colorectal cancer in USA (unspecified route)
- 14 Aug 2001 Preclinical development for Colorectal cancer in USA (Unknown route)